109 related articles for article (PubMed ID: 29025908)
1. A germ-line deletion of APOBEC3B does not contribute to subtype-specific childhood acute lymphoblastic leukemia etiology.
Wallace AD; Francis SS; Shao X; de Smith AJ; Walsh KM; Mckean-Cowdin R; Ma X; Dahl G; Barcellos LF; Wiemels JL; Metayer C
Haematologica; 2018 Jan; 103(1):e29-e31. PubMed ID: 29025908
[No Abstract] [Full Text] [Related]
2. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
3. Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
Radmanesh H; Spethmann T; Enßen J; Schürmann P; Bhuju S; Geffers R; Antonenkova N; Khusnutdinova E; Sadr-Nabavi A; Shandiz FH; Park-Simon TW; Hillemanns P; Christiansen H; Bogdanova N; Dörk T
Breast Cancer Res Treat; 2017 Feb; 162(1):31-37. PubMed ID: 28062980
[TBL] [Abstract][Full Text] [Related]
4. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
[TBL] [Abstract][Full Text] [Related]
5. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
[TBL] [Abstract][Full Text] [Related]
6. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
Gansmo LB; Sofiyeva N; Bjørnslett M; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
Sci Rep; 2021 Dec; 11(1):23463. PubMed ID: 34873230
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3B deletion impacts on susceptibility to acquire HIV-1 and its advancement among individuals in western India.
Singh H; Marathe SD; Nain S; Nema V; Ghate MV; Gangakhedkar RR
APMIS; 2016 Oct; 124(10):881-7. PubMed ID: 27522954
[TBL] [Abstract][Full Text] [Related]
8. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population.
Göhler S; Da Silva Filho MI; Johansson R; Enquist-Olsson K; Henriksson R; Hemminki K; Lenner P; Försti A
J Cancer Res Clin Oncol; 2016 Jan; 142(1):273-6. PubMed ID: 26320772
[TBL] [Abstract][Full Text] [Related]
9. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
10. [APOBEC3B-induced mutagenesis in cancers].
Takaori-Kondo A
Seikagaku; 2016 Oct; 88(5):576-81. PubMed ID: 29624320
[No Abstract] [Full Text] [Related]
11. APOBEC3B deletion and risk of HIV-1 acquisition.
An P; Johnson R; Phair J; Kirk GD; Yu XF; Donfield S; Buchbinder S; Goedert JJ; Winkler CA
J Infect Dis; 2009 Oct; 200(7):1054-8. PubMed ID: 19698078
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription.
Chen Y; Hu J; Cai X; Huang Y; Zhou X; Tu Z; Hu J; Tavis JE; Tang N; Huang A; Hu Y
Antiviral Res; 2018 Jan; 149():16-25. PubMed ID: 29129707
[TBL] [Abstract][Full Text] [Related]
13. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
Marouf C; Göhler S; Filho MI; Hajji O; Hemminki K; Nadifi S; Försti A
BMC Cancer; 2016 Feb; 16():165. PubMed ID: 26920143
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
Wang S; Jia M; He Z; Liu XS
Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
[TBL] [Abstract][Full Text] [Related]
15. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
16. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK
Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3B: pathological consequences of an innate immune DNA mutator.
Burns MB; Leonard B; Harris RS
Biomed J; 2015; 38(2):102-10. PubMed ID: 25566802
[TBL] [Abstract][Full Text] [Related]
18. Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases.
Durfee C; Temiz NA; Levin-Klein R; Argyris PP; Alsøe L; Carracedo S; Alonso de la Vega A; Proehl J; Holzhauer AM; Seeman ZJ; Liu X; Lin YT; Vogel RI; Sotillo R; Nilsen H; Harris RS
Cell Rep Med; 2023 Oct; 4(10):101211. PubMed ID: 37797615
[TBL] [Abstract][Full Text] [Related]
19. APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
Schmitt C; Lucius R; Synowitz M; Held-Feindt J; Hattermann K
Oncol Rep; 2018 Nov; 40(5):2742-2749. PubMed ID: 30226610
[TBL] [Abstract][Full Text] [Related]
20. The surprising activities of APOBEC3B and 5-fluorouracil.
Walton EL
Biomed J; 2015; 38(2):97-100. PubMed ID: 25872558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]